212 related articles for article (PubMed ID: 20002740)
1. Xeomin in the treatment of cervical dystonia.
Benecke R
Eur J Neurol; 2009 Dec; 16 Suppl 2():6-10. PubMed ID: 20002740
[TBL] [Abstract][Full Text] [Related]
2. Clinical efficacy and tolerability of Xeomin in the treatment of blepharospasm.
Jankovic J
Eur J Neurol; 2009 Dec; 16 Suppl 2():14-8. PubMed ID: 20002742
[TBL] [Abstract][Full Text] [Related]
3. Routine use of Xeomin in patients previously treated with Botox: long term results.
Dressler D
Eur J Neurol; 2009 Dec; 16 Suppl 2():2-5. PubMed ID: 20002739
[TBL] [Abstract][Full Text] [Related]
4. Comparison of botulinum neurotoxin preparations for the treatment of cervical dystonia.
Chapman MA; Barron R; Tanis DC; Gill CE; Charles PD
Clin Ther; 2007 Jul; 29(7):1325-37. PubMed ID: 17825685
[TBL] [Abstract][Full Text] [Related]
5. A new botulinum toxin (Xeomin) for cervical dystonia and blepharospasm.
Med Lett Drugs Ther; 2010 Nov; 52(1351):90-1. PubMed ID: 21068703
[TBL] [Abstract][Full Text] [Related]
6. Botulinum toxin therapy for cervical dystonia.
Jankovic J
Neurotox Res; 2006 Apr; 9(2-3):145-8. PubMed ID: 16785112
[TBL] [Abstract][Full Text] [Related]
7. Botulinum toxin in blepharospasm and oromandibular dystonia: comparing different botulinum toxin preparations.
Bhidayasiri R; Cardoso F; Truong DD
Eur J Neurol; 2006 Feb; 13 Suppl 1():21-9. PubMed ID: 16417594
[TBL] [Abstract][Full Text] [Related]
8. Botulinum toxin for treatment of dystonia.
Dressler D
Eur J Neurol; 2010 Jul; 17 Suppl 1():88-96. PubMed ID: 20590814
[TBL] [Abstract][Full Text] [Related]
9. Xeomin: an innovative new botulinum toxin type A.
Frevert J
Eur J Neurol; 2009 Dec; 16 Suppl 2():11-3. PubMed ID: 20002741
[TBL] [Abstract][Full Text] [Related]
10. A guide to dosing in the treatment of cervical dystonia and blepharospasm with Xeomin®: a new botulinum neurotoxin A.
Pagan FL; Harrison A
Parkinsonism Relat Disord; 2012 Jun; 18(5):441-5. PubMed ID: 22405829
[TBL] [Abstract][Full Text] [Related]
11. Reply: Botulinum toxin type B vs. type A in toxin-naïve patients with cervical dystonia: randomized, double-blind, noninferiority trial.
Mueller J
Mov Disord; 2009 May; 24(7):1098-9; author reply 1100. PubMed ID: 18942082
[No Abstract] [Full Text] [Related]
12. BotB (botulinum toxin type B): evaluation of safety and tolerability in botulinum toxin type A-resistant cervical dystonia patients (preliminary study).
Truong DD; Cullis PA; O'Brien CF; Koller M; Villegas TP; Wallace JD
Mov Disord; 1997 Sep; 12(5):772-5. PubMed ID: 9380065
[TBL] [Abstract][Full Text] [Related]
13. Botulinum toxin treatment of axial and cervical dystonia.
Benecke R; Dressler D
Disabil Rehabil; 2007 Dec; 29(23):1769-77. PubMed ID: 18033602
[TBL] [Abstract][Full Text] [Related]
14. Botulinum toxin type B vs. type A in toxin-naïve patients with cervical dystonia: Randomized, double-blind, noninferiority trial.
Pappert EJ; Germanson T;
Mov Disord; 2008 Mar; 23(4):510-7. PubMed ID: 18098274
[TBL] [Abstract][Full Text] [Related]
15. Long-term efficacy and safety of incobotulinumtoxinA injections in patients with cervical dystonia.
Dressler D; Paus S; Seitzinger A; Gebhardt B; Kupsch A
J Neurol Neurosurg Psychiatry; 2013 Sep; 84(9):1014-9. PubMed ID: 23687362
[TBL] [Abstract][Full Text] [Related]
16. A long-term follow-up of botulinum toxin A in cervical dystonia.
Mohammadi B; Buhr N; Bigalke H; Krampfl K; Dengler R; Kollewe K
Neurol Res; 2009 Jun; 31(5):463-6. PubMed ID: 19278576
[TBL] [Abstract][Full Text] [Related]
17. [Use of botulinum neurotoxin therapy].
Mukai Y; Kaji R
Brain Nerve; 2011 Jul; 63(7):775-84. PubMed ID: 21747148
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia.
Brashear A; Lew MF; Dykstra DD; Comella CL; Factor SA; Rodnitzky RL; Trosch R; Singer C; Brin MF; Murray JJ; Wallace JD; Willmer-Hulme A; Koller M
Neurology; 1999 Oct; 53(7):1439-46. PubMed ID: 10534248
[TBL] [Abstract][Full Text] [Related]
19. Adverse events with botulinum toxin treatment in cervical dystonia: How much should we blame placebo?
Duarte GS; Rodrigues FB; Ferreira JJ; Costa J
Parkinsonism Relat Disord; 2018 Nov; 56():16-19. PubMed ID: 29910156
[TBL] [Abstract][Full Text] [Related]
20. Cost-utility analysis of botulinum toxin type A products for the treatment of cervical dystonia.
Kazerooni R; Broadhead C
Am J Health Syst Pharm; 2015 Feb; 72(4):301-7. PubMed ID: 25631837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
